metaEvidence - overview

button bars forest bayes pooled summary circles


			deaths (OS)
non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population
versus atezolizumab plus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel	1	0.80 [0.65; 0.99], 1 RCT, I2=0% conclusive unassessable degree of certainty
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1	0.76 [0.63; 0.92], 1 RCT, I2=0% unassessable degree of certainty
	atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1	0.85 [0.71; 1.02], 1 RCT, I2=0% inconclusive result
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	2	0.78 [0.64; 0.96], 1 RCT, I2=0% conclusive unassessable degree of certainty
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel	1	0.79 [0.64; 0.98], 1 RCT, I2=0% conclusive unassessable degree of certainty
versus pemetrexed plus platin
	atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin	1	0.81 [0.64; 1.03], 1 RCT, I2=0% inconclusive result
	pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin	1	0.90 [0.42; 1.92], 1 RCT, I2=0% inconclusive result
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	0.49 [0.38; 0.64], 1 RCT, I2=0% conclusive unassessable degree of certainty